Budgets for conducting research in WA Health

Katherine Coltrona Senior Policy Officer, Department of Health

18 November 2016

SEMINAR HANDOUT:

ADDITIONAL NOTES AND RESOURCES

CONTENTS:

ADI	DITIONAL INFORMATION	1
1.1	National influences on Research Governance	2
1.2	WA Health Influences on Research Governance	
1.3	Principles to Consider when Preparing a Budget	6
1.4	Calculating Costs – Helpful Resources	9
1.5	Funding considerations	. 16
1.6	Entering the Costs and Funding into the RGS	. 17
1.7	Accountancy	. 22
1.8	Resources	22

© Department of Health 2016

Copyright to this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.

.

1 ADDITIONAL INFORMATION

Overview

The world of research is a constantly changing environment, greater accountability and sustainability means that organisations cannot rely on what was acceptable even 10 years ago. To be competitive, to achieve that elusive grant or sponsorship, researchers must balance the skills of ethical and scientific endeavour with project management. An increasingly important area is identifying costs, matching funding and then recovering costs. This seminar will provide strategies for developing budgets (identifying costs and funding), as well as an introduction to helpful templates and the new Research Governance Service (RGS) information system to be accessible to researchers in November 2016.

Influences on Change in Practice

In today's economic environment good clinical practice equates to sound financial governance, therefore all research projects must have rigorous financial management processes in place. It is no longer acceptable to:

- conduct a project with only ethics approval with limited information of funding source and amount
- accept sponsors budgets without question with no auditing of expenditure or payments
- perform all tests as standard of care, thereby transferring the cost to supporting departments
- pool all funding into one account without traceability
- allow Health Service Providers (HSPs) to cover deficits in funding without prior approval.

Financial management that is accurate, transparent and justifiable will ensure:

- Australia remains competitive as clinical research destination
- grant applications are competitive
- departments are reimbursed for actual time and procedures (accurate costing and invoicing)
- budgets reflect the Protocol not the sponsor's proposed budget
- financial risk reduced to organisation (funding covers costs)
- projects can continue until completion
- participants have continued access to treatments
- staff employment is maintained
- funding is restricted for purpose (correct accounts).

1.1 National influences on Research Governance

1.1.1 Research Governance Handbook

To understand the requirement for research governance and its components, investigators should refer to the National Health and Medical Research Council (NHMRC) Research Governance Handbook: Guidance for the national approach to single ethical review (December 2011) http://hrep.nhmrc.gov.au/ uploads/files/research_governance_handbook.pdf. Some extracts are provided below:

'A critical element of the new Single Ethical Review process is the need for research governance to be understood as comprising distinct elements ranging from the consideration of budgets and insurance, to the management and conduct of scientific and ethics review. In recent years, the concept of research governance has grown from being considered an ancillary responsibility of the Human Research Ethics Committee (HREC) to one that is understood as the responsibility of the institution where the research is being conducted.

An institution's responsibilities in the governance of research are described in the:

- NHMRC/Australian Research Council (ARC)/Universities Australia Australian Code for the Responsible Conduct of Research (2007) (the Code) http://www.nhmrc.gov.au/guidelines-publications/r39
- NHMRC/ARC/Australian Vice Chancellors' Committee National Statement on Ethical Conduct in Human Research (2007) (the National Statement) http://www.nhmrc.gov.au/guidelines/publications/e72.

The institutional consideration as to whether an individual research project is a good fit for the institution at the time it is proposed is the 'site assessment' process, sometimes known as 'research governance review'. This process takes into account the ethical review upon which the institution has chosen to rely, **institution-specific considerations such as resources, budget**, risk management, and applicable legal, regulatory, jurisdictional and other administrative requirements. The outcome of the site assessment is an institutional authorisation of a research project or a decision not to authorise a specific project.'

1.1.2 National Statement

The National Statement 5.2.7 states 'A researcher should disclose to the review body the amount and sources or potential sources of funding for the research.' This is because it is unethical to conduct a project if it is not financially viable. Therefore the investigator should consider:

- are the financial parameters of the project justified and have they been clearly documented and reviewed and approved?
- how will participants been catered for, i.e. is there adequate resources for the participants and the project to continue?
- have the participants been informed of the funding source so they can make an informed decision?

1.1.3 Good Practice Process

As part of the initiative to have more efficient research governance authorisation, the NHMRC has developed the Good Practice Process for Site Assessment and Authorisation Phases of Clinical Trial Research Governance (the Good Practice Process) 2015

https://www.nhmrc.gov.au/research/clinical-trials/development-good-practice-process-site-assessment-and-authorisation-clinica

The Good Practice Process aims to streamline the site assessment and site authorisation of clinical trials by:

- outlining a set of principles and critical success factors for site assessment and site authorisation
- detailing a set of planning and preparation activities that can made a site more responsive to commencing clinical trials
- proposing a streamlined workflow for site assessment and authorisation.

Figure 1 highlights that resourcing and budgets as a site based responsibility, should be addressed by the Sponsor, Principal Investigator (PI) and Institution streams in the feasibility and document preparation stages of the good practice process to ensure the site has the resources and capacity within a given budget.

1.1.4 Clinical Trials Ready

This NHMRC led process will recognise that clinical trial sites, including public and private hospitals and other organisations are 'ready, willing and able' to carry out high quality clinical trials in a timely, transparent and efficient manner. One of the criteria is transparent costs and overheads.

1.1.5 IHPA Standard Costs for Clinical Trials

The Independent Hospital Pricing Authority (IHPA) has developed a table of standard costs for conducting clinical trials in Australia called the Determination of standard costs associated with conducting clinical trials in Australia June 2015

https://www.ihpa.gov.au/sites/g/files/net636/f/publications/determination of standard costs associ ated_with_clinical_trials_in_australia.pdf . This determination does not bind jurisdictions and should be used as a guide to cost all types of clinical trials and negotiate funding with sponsors.

1.1.6 National Costing for Research

IHPA has conducted a costing study to assess the feasibility of transitioning funding for teaching, training and research (TT&R) to an activity based funding (ABF) system by 30 June 2018. For ABF purposes, the definition of research is defined as 'the public health service's contribution to maintain research capability, excluding the costs of research activities that are funded from a source other than the state or territory or provided in kind.' It is therefore imperative that WA Health can cost the States' contribution for supporting research.

Research Skills Seminar Series 2016

		Clinical Trial – Feasibi	lity Assessment to Site Autho	risation	
	Feasibility Assessment	Document Preparation	Document Submission	Site Assessment and Ethics Review	Site Authorisation
Commercial Sponsor / CRO	Identify and decide on potential trial sites, Principal Investigators, Coordinating Principal Investigator and lead HREC Consider patient recruitment requirements and sample size required for protocol Establish if potential sites are using nationally agreed standards, guidelines, contracts, standard costs etc, and, if not, identify any issues that might have an impact on the suitability of a potential site	Develop/provide research protocol and draft contract/budget Recommend standard of care definition(s) in the research protocol Submit a Non-Disclosure Agreement or Confidentiality Agreement to the PI Finalise all documents required by PIs and CPIs to fulfil ethics and site assessment requirements		Receive copy of ethics approval certificate/letter and approved documents from CPI or HREC	Receive site authorisation/s from Pls Register trial with clinical trials registry if not previously registered Notify trial to TGA if required
Principal Investigator/s	In association with institution (as appropriate): Determine whether participation requirements are acceptable Determine capacity of proposed project team to participate in a trial within the proposed time frame Determine whether sufficient participant recruitment can take place at site	Determine institutional requirements for site assessment and authorisation Communicate with sponsor re. document requirements Finalise all documents for site assessment Review documents with institution as necessary	Submit site assessment documents to institution	Receive copy of ethics approval certificate/letter from CPI and provide to institution	Receive notification of site authorisation from institution and provide to sponsor
CPI/delegate	Determine capacity and time required to prepare ethics application	Finalise documents for submission to HREC Review ethics application documents with HREC administrator (or equivalent) as necessary	Submit ethics application to HREC	Receive HREC approval certificate/ letter and approved documents and provide to PIs	
HREC			Accept ethics application and record in database	Conduct ethics review (including preceding or concurrent scientific review) Communicate with CPI if further information or amendments are required during review Provide approval letter and documents to CPI or CRO/Sponsor	
Institution (RGO, Research Director, CFO etc)	In association with the Principal Investigator/s (as appropriate): Determine if clinical trial is consistent with institution's mission and research priorities Assess availability of required institutional resources Identify any other contribution the institution may make to the clinical trial Communicate any special requirements that are specific to the institution and/or jurisdiction to the Sponsor	Approve proposed contract and budget Engage early with relevant support departments or equivalent Provide advice on institutional requirements for site assessment and authorisation as required	Accept documents for site assessment and record in database	Assess site assessment documents Monitor or coordinate delegate review/s and approval/s Receive HREC approval certificate/ letter and approved documents from the PI Liaise with PIs as required regarding any further required documentation Complete assessment	Authorise clinical trial (CEO or delegate) Notify PI of site authorisation

Figure 1. The high level activities, roles and responsibilities for the various components of the site assessment and authorisation process

FIGURE 1: NHMRC GOOD PRACTICE PROCESS SWIM LANE

1.2 WA Health Influences on Research Governance

1.2.1 Research Governance Framework

The <u>Research Policy Framework</u> specifies the research requirements that all Health Service Providers (HSPs) must comply with in order to ensure effective and consistent research activity across the WA health system.

Under this policy framework HSPs and the Department of Health must comply with all mandatory requirements related to the WA Health research governance framework including:

- OD 0411/12 WA Health Research Governance Policy and Procedures 2012 (external site)
- OD 0446/13 WA Health Research Governance and Single Ethical Review Standard Operating Procedures 2013 (external site).

The WA Health research governance framework and single ethical review of <u>multi-centre</u> <u>research</u> has affiliated <u>ethics</u> and <u>governance</u> forms and documents which support the implementation of mandatory requirements.

From December 2016, the ethics and governance application forms, including the Budget Form, which you wish to submit to a WA Health HREC or Research Governance (RG) Office in 2017, must be completed in the Research Governance Service.

2.2.2 Research Governance Service



The Research Governance Service (RGS) is a web based IT system to support the WA Health research governance framework and allow WA to participate in national initiatives, including the National Mutual Acceptance (NMA) process and National Aggregated Statistics for Clinical Trials.

It provides a collaborative workspace for investigators, project members, sponsors, sites, Research Governance Officers (RGOs) and Human Research Ethics Committees (HRECs) to govern and report on research through the life cycle of the project, from initial application to publication.

From December 2016, all new research projects requiring approval to be conducted within WA Health or accessing WA Health participants, data or tissue, must utilise the RGS.

The RGS will be implemented in 2 stages:

Stage 1 will meet the requirements of the NMA by allowing the submission and approval of research projects online. This stage encompasses the creation of users and research projects; the completion, Hospital Administrator authorisation and submission of ethics and governance applications; the review and approval by HRECs and RGOs, and site authorisation for WA Health sites involved in the research project. WA Health will work towards participating in the NMA in 2017.

Stage 1 will not involve monitoring. Monitoring forms will have to be sent to the reviewing HREC and RG Offices outside the RGS until Stage 2 is implemented.

Stage 2 will provide the ability for investigators, sponsors, sites, RGOs and HRECs to monitor and close authorised research projects. This stage encompasses the completion, submission, review and approval of monitoring forms (i.e. amendments; safety, progress and final reports; and complaints). Investigators will have the ability to add publication details to a closed or archived research project. Stage 2 will also include the migration of active and closed projects from WA Health ethics and governance office's databases to allow for WA Health-wide reporting on past and present research activity.

1.2.3 Financial Policy

Financial management of research within WA Health is also influenced by the:

- Health Services Act 2016 (WA)
- Financial Management Act 2006 (WA)
- Government Financial Responsibility Act 2000
- Treasurer's Instructions (TI)
- WA Health Financial Management Manual (FMM) refer to the overhead policy and classifying and accounting for funds in WA Health.

A standard model for the management of clinical research funds is being developed by the Department of Health in collaboration with the HSPs and relevant stakeholders, to ensure current practices comply with relevant legislation and the Tls. Additionally, this reform process will enable the pooling of shared funds across multiple projects to support research capacity within the HSPs.

1.3 Principles to Consider when Preparing a Budget

1.3.1 Principles

A budget should be:

- **Accurate** it should contain the best estimate of all 'research activity' costs and funding, including those that are provided in-kind
- **Transparent** it should itemise (as much as possible) all activity and procedure items that are outlined in the Protocol, as well as the equivalent funding items itemised in the research agreements (e.g. grant, clinical trial research agreement)
- Justifiable only document research activity and base quotes on actual costs not just fees. Consider only the costs to the site, not the whole project e.g. if your Human Research Ethics Committee (HREC) did not undertake the ethical review of a project then there will be no cost equated to your site.

1.3.2 Financial Management Requirements

The **OD 0411/12 WA Health Research Governance Policy and Procedures 2012** outlines the following requirements:

- 1. The budget must document the cost/funding of all research activity in the Protocol which is secondary to the primary purpose of providing patient care (above standard of care)¹.
- After assessing the Protocol, the estimated costs for the research department must be
 documented in the RGS Budget Form (Figure 6) by the PI/delegate, including overheads
 (as per the FMM). The Business Manager should provide assistance with costing salaries,
 including on costs and specific items where required. Ethics and governance review costs
 should also be included.
- 3. Upon request from the PI/delegate, the supporting departments (Pharmacy, Pathology, Imaging etc.) must review the Protocol and document their costs in the RGS Budget Form and provide authorisation.
- 4. The PI/delegate must then document on the Budget Form the comparable monetary or in kind support (funding) for both the research and supporting departments costs for the project. **(Figure 7).** A total funding value will be calculated at the top of the form.
- 5. The PI/delegate must cover all costs with adequate funding from either:
 - o external monetary funding for commercially sponsored projects
 - o a combination of monetary funding and 'in kind' support for non-commercial sponsored research or institutional unfunded research.
- 6. With projects involving external sponsors, negotiations for funding should be based on established WA Health fee structures and justifiable costs. The RGO should provide assistance to the PI/delegate with this negotiation as required. Due to confidentiality, external sponsors must not be given access to the Budget Forms. The agreed funding and payment schedule must then be documented in the research agreement.
- 7. Although budgets should not include the Goods and Services Tax (GST), it should be noted that in the payment schedule of the legal agreement GST is applicable if the sponsor is an Australian entity.
- 8. The Site Specific Assessment (SSA) Form and Budget Form, with any supporting service agreements, should be reviewed and electronically authorised by the Heads of Research and Supporting Departments, Business Manager and Divisional Director (and Regional Director within WACHS) prior to review by the RGO. Research governance review fees will be levied for all commercially sponsored research. Final authorisation is given by the Chief Executive/delegate.

1.3.3 What will Influence the Budget

The following factors will influence the budget:

- complexity of the Protocol i.e. complex clinical trial versus simple project
- length of project as costs will be incurred across life of the project
- number of sites and supporting departments
- number of participants (people, data, samples)
- funder type i.e. commercial versus non-commercial.

It excludes curriculum-based research projects. Indirect or by-product research is considered as part of normal patient care and is not included in the national standard.

¹ According to the "Australian Hospital Patient Costing Standards v 2.0" 2011 definition, research is an activity where the primary aim is the advancement of knowledge through:

Observation, data analysis and interpretation, or other means that are secondary to the primary purpose of providing patient care; or

Activities associated with patient care where additional components or tasks exist (for example, the addition of control group in a cohort study).

1.3.4 Types of Costs to Consider

The <u>IHPA Determination of standard costs for clinical trials June 2015</u> can be used as a guide when considering costs that should be included in the budget. They are broken into Major Categories:

Feasibility assessment	Clinical resources
Ethics approval	Trial operation
Site-specific assessment	Participant related
Trial initiation	Amendment processing
Patient accrual	Site closeout visit
Clinical services	Record archiving
Pharmacy/Investigation drug related	Drug return/destruction
Biospecimen related	Biospecimen transfer/destruction

Some additional ones to consider include:

Feasibility: this may not be covered by funding as it is activity that occurs prior to the commencement of the project.

- protocol development or review
- grant application or budget preparation
- · Confidentiality Agreement review
- site review
- ICT setup or development
- ethics and governance applications.

NB: Consider who will pay for this activity if the project does not progress.

Shared (Indirect): these are non-project specific costs that can be shared to support staff salaries and wages, staff professional development and training, grants for investigator-led unfunded projects, research equipment (un-funded through the Asset Investment Program), administrative costs and utilities.

- Research Department personnel time investigators, clinical support, administrators, business support, statistical/economist support, interpreters
- Research Department salary based procedures e.g. vital signs, biospecimen collection, screen failures, unscheduled visits, early withdrawal
- salary based overhead
- training
- non-project specific equipment
- general administration consumables
- utilities non-project specific ICT, telecommunications, buildings

NB: IHPA defines indirect costs as only the overhead

Project specific (Direct): these are costs that are directly related to the project

- all Supporting Department costs
- · drugs and devices
- Research Department procedures/investigations/clinical tests if they involve more than just salaries e.g. colonic biopsy
- project specific equipment & ICT
- travel, transport
- licences
- participant payments travel, meals, accommodation
- record/data management outside Research Department
- amendments
- project specific reporting (if involves more than research department salaries) statistical analysis, monitoring
- archiving
- translation policies, seminars, publications

1.4 Calculating Costs – Helpful Resources

2.4.1 Research Department

The PI/delegate should calculate the costs for the research department by considering the:

- a) schedule of procedures/visits in the Protocol
- b) sponsors budget spreadsheet for their schedule of procedures/visits
- c) IHPA Determination of Standard Costs to consider items not addressed in a) or b)
- d) Departmental costs and Medicare Benefits Schedule for non-salary based procedures http://www9.health.gov.au/mbs/search.cfm

Salary based procedural costs

Clinical trial per participant payments are often calculated based on salary based procedures that can be calculated by multiplying the project member's time (e.g. investigator, research nurse or trial coordinator) by their salary rates plus on costs. These rates can be calculated using the WA Health Research Budget Template V3.0 May 2016 (Excel 153KB) using the following steps:

- 1. Identify the salary rates of the Research Department staff and ensure the WA Award Rates sheet is current, update as necessary (Figure 2).
- 2. Complete the Salary Calculator Sheet for the Research Department staff by entering in their Award Rates. Enter the on cost rate and overhead rate (Figure 3). The direct salary costs and on costs will flow into the Per Participant Salary Sheets (Figure 4 & 5). The following should be noted:
 - o on costs should be applied in accordance with FMM, the internal rate is 24%
 - overheads cover indirect costs to specialty/organisation including rent, building maintenance & utilities, support personnel & departmental charges, equipment maintenance & IT infrastructure
 - overheads should be applied in accordance with FMM, rates range from 0% (NHMRC, charities, DoH), 10%, 25% (commercial company >\$10M)

- overheads should only be applied to research department salary costs (e.g. under the major category: Clinical Resources). Generally applied to participant payments as these are made up of salaries
- overheads should be calculated separately from salaries so that it can be waived if required. This is separately identified in the RGS Budget Form
- caution should be used when using IHPA's salary rates as they are fully absorbed, which includes a 33% overhead.
- 3. Complete either the Per Participant Salary (simple) costing template (Figure 4) or the Per Participant Salary (complex) costing template (Figure 5A & B):
 - The Simple template allows the PI/delegate to enter any salary related procedures or visits. There is a separate section for unscheduled procedures/visits. The time taken in hours for each procedure/visit is then calculated for each project member and costed. The template provides salary costs for the project for each project member (highlighted in yellow), and the cost of each procedure/visit (highlighted in green).
 - The Complex template allows the PI/delegate to enter any salary related procedures plus unscheduled procedures/visits and enter the time for each procedure/visit as well as the number of times each procedure/visit occurred. The time taken in hours for each procedure/visit is then calculated for each project member and costed. The template provides salary costs for the project for each project member (highlighted in yellow), as well as each cost for each procedure/visit (highlighted in green). Figure 5A shows the normal procedures and Figure 5B shows unscheduled procedures.

NB: Consider adjusting for future wage increases.

1.4.2 Supporting Departments

- 1. As part of the feasibility assessment the PI/delegate must invite all supporting departments that will be required to provide a service for the project (including normal standard of care) to review the Protocol and provide a quote on the Budget Form. All research projects that involve the use of a pharmaceutical must obtain authorisation from Pharmacy.
- 2. Supporting departments should review the Protocol to ascertain any research related (above standard of care) procedures that need to be provided and document their costs/authorisation in a timely manner (within 2 weeks). Additional time may be required where the project involves radiation exposure, possible dosimetry assessment and Radiological Council approval. If the procedure is deemed standard of care this should be added as a comment and the cost marked as \$0.00.
- Supporting departments should consider the Medicare Benefits Scheme (MBS) and IHPA
 recommendations when calculating their costs (140% MBS). Additionally, they should be
 open to negotiating costs or in-kind support with the PI/delegate for non-commercial
 projects.
- 4. Payments for services provided by the supporting departments are invoiced directly to the research department (based on an internal agreement) unless the supporting department has a separate external agreement with the sponsor. When supporting departments are invoicing the research department the particular project should be identified in the general ledger.

FIGURE 2: WA AWARD RATES 2015 http://www.health.wa.gov.au/awardsandagreements/

AMA: 1 October 201	ll relevant allo 5.40br/wook						nsultant ra	
Aria. 10000bei 201 Level	Annual Salary	Hourly Sal-	arıı				nsultant ra ot have ad	
Consultant Yr 5	\$ 216,088.00		03.89		•			
Consultant Yr 8	\$ 250,148.00		20.26				with your E	ousines
Consultant Yr 9							ly to your	
Consultant 11 3	\$ 262,656.00	\$ 1	26.28	Departm	nent's Co	nsultants		
ANF: 1 July 2015:	38hr/week							
Level	Annual Salary	Hourly Sal-	aru					
_evel 2.1	\$ 86,555.00		43.80					
evel 2.2	\$ 88,320.00		44.70					
_evel 2.3	\$ 90,123.00	\$	45.61					
_evel 2.4	\$ 91,962.00		46.54					
SRN Level 1		-						
			52.60					
SRN Level 2	\$ 107,279.00		54.29					
SRN Level 3	\$ 110,723.00	\$	56.03					
HSU: 1 July 2015	38hr/week							
General Division Level	Annual Salary	Hourly Sal-	arıı					
general Division Level G-3.1			31.31					
		\$						
G-3.2	\$ 63,491.00	\$	32.13					
G-3.3	\$ 65,205.00		33.00					
G-3.4	\$ 67,862.00		34.34					
G-4.1	\$ 70,633.00	\$	35.75					
G-4.2	\$ 72,711.00	\$	36.80					
G-4.3	\$ 75,738.00	\$	38.33					
G-5.1	\$ 77,314.00	\$	39.13					
G-5.2	\$ 79,477.00		40.22					
G-5.3	\$ 81,704.00	\$	41.35					
G-5.4	\$ 83,995.00	\$	42.51					
G-6.1	\$ 88,411.00	-	44.74					
G-6.2	\$ 91,685.00	-	46.40					
G-6.3	\$ 96,345.00		48.76					
G-7.1	\$ 98,837.00		50.02					
G-7.2	\$ 101,991.00	\$	51.61					
G-7.3	\$ 105,261.00	\$	53.27					
G-8.1	\$ 110,042.00	\$	55.69					
G-8.2	\$ 113,958.00	\$	57.67					
D 4 1 10111 1								
Professional Division Lev P-1.1	el Annual Salary \$ 68,629.00	Hourly Sal	ary 34.73					
P-1.2		-	36.80					
		-						
P-1.3	\$ 77,314.00	\$	39.13					
P-1.4	\$ 81,704.00	\$	41.35					
P-1.5	\$ 88,411.00		44.74					
P-1.6	\$ 96,345.00		48.76					
P-2.1	\$ 98,837.00	\$	50.02					
P-2.2	\$ 101,991.00	\$	51.61					
P-2.3	\$ 105,261.00	\$	53.27					
P-3.1	\$ 110,042.00	\$	55.69					
P-3.2	\$ 113,958.00	\$	57.67					
P-4.1	\$ 120,302.00		60.88					
4.2 □-4.2	\$ 124,437.00		62.97					
P-5.1	\$ 128,972.00		65.27					
5.2 ⊃-5.2	\$ 136,497.00		69.08					
5.2 P-6.1	\$ 142,324.00		72.03					
P-6.2	\$ 148,255.00		75.03					
P-7	\$ 156,921.00	\$	79.41					
P-8	\$ 162,434.00	-	82.20					
P-9	\$ 168,719.00	\$	85.38					

FIGURE 3: SALARY RATES USED ON COSTING TEMPLATES

Salary Rates used in Costing Template						,			
					Salary rates in Simple &				
Standardised staff positions and rates 2015 - 2016:		Equivalent WA levels to IHPA levels			Complex Speadsheets		Comparison a	against IHPA Rates	
						VA Health H	ourly Rates	IHPA Hourly Rate ((fully
			WA Health Hou	rly Rates	WA Health Hourly Rates	ully absort	ed - direct,	absorbed - direct,	, oncosts &
Clinical Resources Positions	IHPA Salary Level/Grade	WA Health Salary Level/Grade	(direct only)		(direct & oncosts)	ncosts & o	erhead costs)	overhead costs)	
Investigator time – Principal investigator	AMA Yr 8-9	AMA Yr 9	\$	126.28	\$ 156.59	3	195.73	\$	226.11
Investigator time – sub/co- investigator	AMA Yr. 5	AMA Yr 5	\$	103.89	\$ 128.82	\$	161.03	\$	199.11
Research nurse time	Clinical Nurse Specialist Yr1-2	ANF Level 2.4	\$	46.54	\$ 57.71	3	72.14	\$	74.79
	RN;								
Clinical research coordinator (non-research nurse) time – equivalent to	Scientist Grade 3-4;								
Clinical Trials Coordinator (CTC)	Pharmacist G 3-5.	HSU G-6.3	\$	48.7€	\$ 60.46	\$	75.58	Ş	82.74
Clinical research coordinator (non-research nurse) time – equivalent to									
Clinical Trials Manager (CTM)	Clinical Nurse Consultant Ga	ANF SRN Level 3	\$	56.03	\$ 69.48	\$	86.85	Ş	93.16
Clinical research coordinator (non-research nurse) time – equivalent to									
Clinical Trials Manager (CTM)/Clinical Trials Coordinator (CTC)	A blended CTM/CTC hourly rate	A blended CTM/CTC hourly rate	\$	52.40	-	\$	81.21	Ş	90.78
Interpreter services			\$	-	\$ -	3		\$	53.91
		Ţ							
Overhead Cost Rate:	25%								
Note: Should only be applied to research deparment salary costs (e.g									
under the IHPA major category: Clinical Resource). Financial									
Management Manual (FMM) for rates: Rates range from 0%, 10%, 25%									
depending on type of project.									
Oncosts Cost Rate:	24%								
WA Health Hourly Rates based on salary costs (direct + oncosts) – Refer									
to Financial Management Manual (FMM) for rates:									
On-costs only for staff employed directly by WA Health;									
On-cost internal rate: 24%									
On-cost external rate: Non-medical staff 29% + Medical staff 40%									

FIGURE 4: SIMPLE PER PARTICIPANT SALARY COSTING TEMPLATE

Note: Salary time is in hours

Costing Template for Clinic	al Resources' Sal	aries per Partici,	oant (Simple)			
					Calculated Cost based on	Calculated Cost based
	Investigator Time (no	Research Nurse Time	CTC Time (no	CM Time (no	Time (hrs) and Salary (no	on Time and Salary
Procedures or Visits	overhead)	(no overhead)	overhead)	overhead)	overhead)	(including overhead)
Screening	5	5	1	0	\$ 1,131.95	\$ 1,414.93
Week 0	3	5	1	0	\$ 818.77	\$ 1,023.47
Week 2	1	3	0	0	\$ 329.72	\$ 412.15
Week 4	2	4	0	0	\$ 544.01	\$ 680.02
Week 6	1	3	0	0	\$ 329.72	\$ 412.15
Week 8	1	4	0	0	\$ 387.43	\$ 484.28
Week 10	3	8	1	0	\$ 991.90	\$ 1,239.88
Week 12	1	4	0	0	\$ 387.43	\$ 484.28
Week 14	0	6	1	0	\$ 406.72	\$ 508.40
SUB TOTAL	\$ 2,661.98	\$ 2,423.80	\$ 241.85	\$ -	\$ 5,327.64	\$ 6,659.54
Unscheduled Procedures or Visits						
Unscheduled visit	1	2	1	0	\$ 332.47	\$ 415.59
Early withdrawal from treatment	2	5	1	0	\$ 662.18	\$ 827.73
12 Week Safety - week 6	0	1	1	0	\$ 118.17	\$ 147.72
Week 12/ early termination	2	3	1	0	\$ 546.77	\$ 683,46
Unscheduled visit	1	1	1	0	\$ 274.76	\$ 343.45
TOTAL	\$ 3,601.51	\$ 3,116.32	\$ 544.16	\$ -	\$ 7,261.99	\$ 9,077.48

You can enter into the Research Governance Site Specific Assessment Budget Spreadsheet the total individual personnel salaries per participant. OR

You can enter into the Research Governance Site Specific Assessment Budget Spreadsheet the total salaries per individual procedure or visit per participant.

FIGURE 5A: COMPLEX PER PARTICIPANT SALARY COSTING TEMPLATE - Part A Normal Procedures

		time in hours ea	ach person <u>sp</u> i	ends on ea <u>ch i</u>	procedure	Enter numb	er of times i	rocedure occu	rs per visit	(usually 1)												
	Investigator Time (no	Research Nurse Time (no	CTC Time	CM Time (no	Cost per item (based on Time and				•							Week						
rocedures	overhead)	overhead)	overhead)	overhead)	Salary)	Screening		Week 0 Co	st	Week 2 Cost	Week 4		Week 6 Cost	Week 8	Cost	10		Week 12	Cost	Week 14	Cost	Subtota
nformed consent	1	1	. 0)	\$ 214.30	1	\$ 214.30		-	\$ -		\$ -	\$ -		\$ -		\$ -		\$ -		\$ -	
Vital signs	0	1	. 0)	\$ 57.71		\$ 57.71			1 \$ 57.7	1 1	\$ 57.71	1 \$ 57.71	1	\$ 57.71	1	\$ 57.71	1	\$ 57.71	. 1	\$ 57.71	
Medical history	1	1	. 1		\$ 274.76	1	\$ 274.76			\$ -		\$ -	\$ -		\$ -		\$ -		\$ -		\$ -	
hysical exam	1	1	. 0)	\$ 214.30	1	\$ 214.30	1 \$	214.30	\$ -		\$ -	\$ -		\$ -	1	\$ 214.30		\$ -		\$ -	
CG	1	0	0		\$ 156.59	1	\$ 156.59	1 \$	156.59	\$ -	1	\$ 156.59	\$ -		\$ -	1	\$ 156.59		\$ -		\$ -	
Adverse event monitoring	0	3	1		\$ 233.59		\$ -	\$	-	\$ -		\$ -	\$ -		\$ -	1	\$ 233.59		\$ -	1	\$ 233.59	1
Blood draw	1	1	. 0)	\$ 214.30	1	\$ 214.30	0 \$	-	1 \$ 214.3) 1	\$ 214.30	1 \$ 214.30	1	\$ 214.30	1	\$ 214.30	1	\$ 214.30		\$ -	
Questionnaire	0	1	. 0		\$ 57.71		\$ -	1 \$	57.71	1 \$ 57.7	1 1	\$ 57.71	1 \$ 57.71	1	\$ 57.71	1	\$ 57.71	1	\$ 57.71	. 1	\$ 57.71	
Data entry	0	1	. 0		\$ 57.71		\$ -	1 \$	57.71	\$ -	1	\$ 57.71	\$ -	1	\$ 57.71	1	\$ 57.71	1	\$ 57.71	. 1	\$ 57.71	
Subtotal	\$ 782.94	\$ 577.10	\$ 120.92	\$ -	\$ 1,480.96		\$ 1,131.99	5 \$	818.77	\$ 329.7	2	\$ 544.01	\$ 329.72		\$ 387.43		\$ 991.90		\$ 387.43		\$ 406.72	\$ 5,327
Inscheduled Procedures																						
Inscheduled visit	1	2	1		\$ 332.47																	
arly withdrawal from treatm	2	5	1		\$ 662.18																	1
12 Week Safety - week 6	0	1	. 1		\$ 118.17																	1
Week 12/ early termination	2	3	1		\$ 546.77																	1
Unscheduled visit	1	1	. 1		\$ 274.76																	
Subtotal	\$ 939.52	\$ 692.52	\$ 302.31	\$ -	\$ 1,934.35																	
OTAL	\$ 1,722.46	\$ 1,269.61	\$ 423.24	S -	\$ 3,415.31																	
					Total salaries	per visit																
					Investigator		\$ 782.94	3 \$	469.76	1 \$ 156.5	9 2	\$ 313.17	1 \$ 156.59	1	\$ 156.59	3	\$ 469.76	1	\$ 156.59	0) \$ -	\$ 2,661
					Research															1		
					Nurse	5	\$ 288.55	5 5	288.55	3 \$ 173.1	3 4	\$ 230.84	3 \$ 173.13	4	\$ 230.84	8	\$ 461.68	4	\$ 230.84	. 6	\$ 346.26	\$ 2,423
					стс		\$ 60.46			0 \$ -		\$ -	0 \$ -	-	\$ -		\$ 60.46	0	\$ -		\$ 60.46	
					CM		\$ -	0 \$	-	0 \$ -		5 -	0 \$ -		\$ -		\$ -		\$ -		\$ -	6
							3 -	0 3		0 3 -	+ '	, , -	0 3 -	U	, -	U	, -	0	3	+	3 -	\$ 5,327
					TOTAL															+		\$ 5,327
Note: Salary time is in hours																						
ou can enter into the Resear																						
ou can enter into the Resear	ch Governanc	e Site Specific	Assessment	t Budget Spre	adsheet the to	tal salaries	per individ	ual visit per p	participan	t.												

FIGURE 5B: COMPLEX PER PARTICIPANT SALARY COSTING TEMPLATE - Part B Unscheduled Procedures

	Enter t	ime in hours ea	ich person sp	ends on each i	procedu	re	Enter number	of times p	ocedure occu	ırs per visit	(usually 1))									
Procedures	Investigator Time (no overhead)	Research Nurse Time (no overhead)	CTC Time (no overhead)	CM Time (no overhead)	Cost p (base Time a Salary	and	Unschedule d visit	Cost	Early withdraw al from treatment	Cost	12 Week Safety - week 6	Cost	Week 12/ early terminatio n	Cost	Unschedul ed visit	Cost		Total		Time Sala (incl	based e and ary luding head)
nformed consent	1	1	0		\$	214.30		\$ -		\$ -		\$ -		\$ -		\$	-	\$	214.30	\$	267
/ital signs	0	1	0		\$	57.71		\$ -		\$ -		\$ -		\$ -		\$	-	\$	519.39	\$	649
Medical history	1	1	1		\$	274.76		\$ -		\$ -		\$ -		\$ -		\$	-	\$	549.52	\$	686
Physical exam	1	1	0		\$	214.30		\$ -		\$ -		\$ -		\$ -		\$	-	\$	642.89	\$	803
ECG	1	0	0		\$	156.59		\$ -		\$ -		\$ -		\$ -		\$	-	\$	626.35	\$	782
Adverse event monitoring	0	3	1		\$	233.59		\$ -		\$ -		\$ -		\$ -		\$	-	\$	467.18	\$	583
Blood draw	1	1	0		\$	214.30		\$ -		\$ -		\$ -		\$ -		\$	-	\$	1,500.08	\$	1,875
Questionnaire	0	1	0		\$	57.71		\$ -		\$ -		\$ -		\$ -		\$	-	\$	461.68	\$	577
Data entry	0	1	0		\$	57.71		\$ -		\$ -		\$ -		\$ -		\$	-	\$	346.26	\$	432
Subtotal	\$ 782.94	\$ 577.10	\$ 120.92	\$ -	\$:	1,480.96		\$ -		\$ -		\$ -		\$ -		\$	-	\$	5,327.64	\$	6,659
Unscheduled Procedures																					
Jnscheduled visit	1	2	1		\$	332.47	1	\$332.47		\$ -		\$ -		\$ -		\$	-	\$	332.47	\$	415
Early withdrawal from treatm	2	_	1		\$	662.18		\$ -	1	\$ 662.18		\$ -		\$ -		\$	-	\$	662.18	\$	827
12 Week Safety - week 6	0	1	1		\$	118.17		\$ -		\$ -	1	\$118.17		\$ -		\$	-	\$	118.17	\$	147
Week 12/ early termination	2	3	1		\$	546.77		\$ -		\$ -		\$ -	1	\$546.77		\$	-	\$	546.77	\$	683
Unscheduled visit	1	1	1		\$	274.76		\$ -		\$ -		\$ -		\$ -	1	\$ 27	_	\$	274.76	_	343
Subtotal	\$ 939.52	\$ 692.52	\$ 302.31	\$ -	\$:	1,934.35		\$332.47		\$ 662.18		\$118.17		\$546.77		\$ 27	4.76	\$	1,934.35	\$	2,417
TOTAL	\$ 1,722.46	\$ 1,269.61	\$ 423.24	\$ -	\$:	3,415.31												\$	7,261.99	\$	9,077
							per visit		_												
					Invest	igator	1	\$156.59	2	\$ 313.17	0	\$ -	2	\$313.17	1	\$ 15	6.59	\$	3,601.51	\$	4,501
					Resea	irch														1	
					Nurse		2	\$115.42	5	\$ 288.55	1	\$ 57.71	3	\$173.13	1	\$ 5	7.71	\$	3,116.32	\$	3,895
					CTC		1	\$ 60.46	1	\$ 60.46	1	\$ 60.46	1	\$ 60.46	1	\$ 6	0.46	\$	544.16	\$	680
					CM		0	\$ -	0	\$ -	0	\$ -	0	\$ -	0	\$	-	\$	-	\$	
					TOTAL													s	7,261.99	Ś	9,077
																$\overline{}$		_			
												-									
ote: Salary time is in hours																					
ou can enter into the Resear	ch Governand	e Site Specific	. Assessmei	nt Budget Sp	readsh	eet the t	otal individua	al personi	nel salaries	per partic	ipant. OR										
ou can enter into the Resear	ch Governand	e Site Specific	c Assessmer	nt Budget Sp	readsh	eet the t	otal salaries	per indivi	dual visit p	er participa	ant.										
hen adding extra visits you	must update	these formula	e e																		

1.5 Funding considerations

1.5.1 Types of Funder and Funding

Funders may be:

- Commercial Company Industry / Contract Research Organisation
- Collaborative Research Group
- Government Commonwealth
- Government State (WA)
- Government State/Territory (Non-WA)
- Not for Profit
- University
- Other e.g. self-funded

Funding may be:

- Grant
- Sponsor
- Fee for service
- In-kind support

1.5.2 Payment type

Payments may be up-front versus recoup basis; adhoc versus regular payments; or bundled versus itemised.

1.5.3 Cost Recovery

For commercial projects there should be full cost recovery. In the cases of non-commercial projects the investigator will have to negotiate with the site and supporting departments if they can provide in-kind support or provide operational funding.

1.5.4 Negotiating with the funder

If possible negotiate with the funder for additional funding. Transparency of costs and knowing your protocol will facilitate this process. Be prepared to give and take within reason and consider renegotiation with your supporting departments.

1.5.5 Funding Agreements

All external funding should have an agreement and it should reflect the budget. Ensure it contains a payment schedule and details whether payments will be bundled or itemised. Consider whether supporting departments will be payed separately and whether invoicing will be direct or there will be a Recipient Created Tax Invoice. Also consider GST.

NB: Don't forget to invoice!

1.6 Entering the Costs and Funding into the RGS

1.6.1 The process to complete and authorise the SSA and Budget forms

In the RGS the Budget Form is separate from the SSA Form. Authorisation within the Budget Form is related to the costs and funding of the project. Authorisation within the SSA Form is related to the whole project (including costs & funding).

The following roles have responsibilities for completing and authorising the costs and funding associated within the project in either the SSA Form or Budget Form:

1. The PI/delegate should:

- add the proposed number of participants for the site and expected project timeframe for the site in the Budget Form 'Department Selection'
- add the research department, third party agencies (e.g. radiology services outside WA Health) and supporting departments to the Budget Form 'Department Selection' and invite Heads of Supporting Departments (HoSDs) to provide a quote
- indicate to the supporting departments the types of 'Service/Support Items' that should be provided by them. This is done be selecting them in under that department in the Budget Form 'Site Project Budget'. This is not mandatory and may be left to the HoSDs to select
- complete the costs and funding for any third party agencies based on the Protocol and authorise them
- complete the costs for the research department based on the Protocol (refer to section 1.4.1) and enter the associated funding
- complete the Budget Form 'Site Project Funding/Support' for the supporting departments once HoSDs have entered and authorised their costs
- once all the funding is entered for the research department, invite your Head of Research Department (HoRD) to authorise the budget for the research department
- authorise the Budget Form 'Site Project Funding/Support' once completed
- sign the SSA Form (PI only, not the delegate) once the Budget Form is authorised and the SSA Form has been marked complete
- Invite the Business Manager, Divisional Director and if applicable Regional Director (WACHS) to sign the SSA Form
- authorise the SSA Form once all signatures are obtained and then submit the both the SSA and Budget forms together to the RG Office.

2. The HoSDs should:

- accept the invitation to the project, complete the costs for their supporting department based on the Protocol and authorise them
- add a comment to the Budget Form if they decide to decline providing a service
- complete the 'Site Project Funding/Support' for their supporting departments if they are prepared to provide in-kind support to cover their costs.

3. The HoRD should:

- accept the invitation to the project, review the research department costs and funding project and provide authorisation for the research department in the Budget Form 'Site Project Budget'.
- 4. The Business Manager, Divisional Director and if applicable Regional Director (WACHS) should:
 - accept the invitation to the project, review the SSA Form and Budget Form and provide authorisation on the SSA Form.

1.6.2 Calculating Research Department costs & funding in the RGS Budget Form

- The salary based Service/Support item costs should be entered into the Budget Form 'Site Project Budget' either as the total salary per project member (Figure 6) or broken down as salaries per procedure/visit for one participant. The amount should then be multiplied by the number of participants (Quantity) to calculate the Total Cost.
- 2. The PI/delegate should then enter any non-salary based costs that will be incurred by the research department. They should:
 - select the relevant Service/Support item
 - enter a cost description if this item does not match what it is called in the department or on the funding agreement
 - enter the cost per item
 - enter the quantity of the item (i.e. the. number of tests x participants x project timeframe in years) to arrive at a total cost
 - select whether the cost is Project Specific (e.g. procedures) or Shared (e.g. salaries)
 - select whether overhead charges apply to a service/support item. Overheads should only be applied to research department salary costs (e.g. under the major category: Clinical Resources). Generally applied to participant payments as these are made up of salaries.
- 3. If the PI/delegate uses the IHPA cost schedule for fixed costs, the PI/delegate should be mindful that costs are often:
 - bundled i.e. they include research department and supporting department costs combined for a specific item (e.g. Feasibility determination – study site visit). Therefore these costs should be unbundled or not replicated in both departments
 - fully absorbed rates i.e. they include 33% overhead. Therefore the overhead should be removed (divide the amount by 1.33), and then the correct FMM overhead applied.
- 4. In clinical trials some costs may be fixed (e.g. archiving) or pass through (e.g. participant travel). Fixed costs are easier to identify and match funding but as pass through costs may only occur on an adhoc basis they may be harder to estimate. For pass through costs ensure the potential number of instances you have estimated is the same for costs and funding. There may also be a capped amount to consider.
- 5. Once the entire research department **(Figure 6)** and supporting department's costs are entered in the Budget Form 'Site Project Budget' (refer to section 1.6.1), the PI/delegate should complete the funding (monetary and in-kind) in the Budget Form

- 'Site Project Funding / Support' to align with the cost items (**Figure 7**). Some funding amounts may cover several cost items.
- 6. A comparison of Total Actual Costs versus Total Funding is provided at the top of the Budget Form with either a Shortfall or Surplus calculated. If the budget is in deficit then an explanation must be provided for how the costs will be met in the General Comments section.
- 7. Once the budget is completed, the PI/delegate will invite the HoRD to authorise the budget for the research department.
- 8. The PI/delegate will then invite the Business Manager, Divisional Director and if applicable Regional Director (WACHS) to review the Budget and SSA forms and sign the SSA Form.

NB: If you calculate costs in the feasibility stage, these costs can be used to formulate a Grant Application.

1.6.3 Documenting costs & funding in the Ethics Application Form

The costs and funding entered into the Ethics Application Form are the total costs and funding for all sites involved with the project that fall within that ethics application. That is, all sites that the reviewing HREC will be giving ethical approval for. It does not include sites that fall under the review of another external HREC.

As not all site authorisations will be completed when submitting an ethics application, the total project costs and funding may be an estimate. The HREC is more interested in the ethical implications related to whether the project has sufficient funding to maintain its activity for the life of the project.

FIGURE 6: COMPLETED RGS RESEARCH DEPARTMENT 'SITE PROJECT BUDGET' (COSTS)





FIGURE 7: COMPLETED RGS RESEARCH DEPARTMENT SITE PROJECT FUNDING / **SUPPORT**



~

~

V

Please select...

Please select...

Please select...

Please select...

Pfizer Australia

Pfizer Australia

Pfizer Australia

Pfizer Australia

s

\$

s

0.00

445.00

520.00

5.330.00

2.020,00

s

\$

+

 \pm

+

1.7 Accountancy

1.7.1 Track expenditure

Investigators should consider maintaining a debit/credit spreadsheet to track actual budget expenditure, this:

- allows financial monitoring of project to ensure viability
- aids future budget planning
- monitors invoicing and sponsor payments, thereby ensuring all items in the agreement are correctly invoiced
- assists renegotiation of the budget if you are providing unpaid services not in original Protocol.

If an Amendment changes the budget, the investigator should update the Budget Form and resubmit it to the RGO with an updated agreement.

1.7.2 What accounts to use for external funds

Currently within WA Health the following accounts can be used for external research funds:

- 1. Externally Restricted Cost Centre (ERCC):
 - Must be external funds.
 - Restricted cash can roll over financial years.
 - Must have a documented special purpose (e.g. CTRA) no blended funds and document use of residual funds.
 - Cannot go into deficit, therefore it cannot operate on a recoup basis if there are insufficient funds in the CC. NOTE: most clinical trials operate on recoup.
 - Set up Requires:
 - o Executed Agreement
 - ERCC form 905-1
- 2. Transitional Externally Restricted Cost Centre (XCC)
 - This allows for pooling of previous SPA money until it is spent.

NB: Current WA Health management of clinical research funds is under review to allow for the pooling of shared costs across projects.

1.7.3 What accounts to use for internal funds

Internal WA Health funds (e.g. Department of Health grants) cannot be managed in ERCCs. Investigators must use an operating account. This does not allow for the roll of funds over fiscal years, therefore requires forward projection outlining fiscal year expenditure. These accounts can go into a deficit but must be managed.

1.8 Resources

1.8.1 Resource staff

- Dedicated administration and finance staff.
- Business Managers can provide information on salaries, on costs, overheads, opening accounts, transferring funds across Health Services.

1.8.2 ICT

- RGS http://ww2.health.wa.gov.au/Health-for/Researchers-and-educators/Research-governance
- Project and financial management software.

1.8.3 Templates

 WA Health Research Budget Template http://ww2.health.wa.gov.au/Articles/N_R/Research-governance-forms

1.8.4 Documents

- Independent Hospital Pricing Authority (IHPA) Determination of standard costs associated with conducting clinical trials in Australia June 2015 https://www.ihpa.gov.au/sites/g/files/net636/f/publications/determination_of_standard_costs_associated_with_clinical_trials_in_australia.pdf
- Published departmental & organisation fee schedules.

1.8.5 Websites

- Medicare Benefits Schedule http://www9.health.gov.au/mbs/search.cfm
- Awards http://www.health.wa.gov.au/AwardsAndAgreements/
- Department of Health
 http://ww2.health.wa.gov.au/Health-for/Researchers-and-educators/Research-governance

http://ww2.health.wa.gov.au/Articles/A E/Clinical-trials-and-research-governance-education

1.8.6 Policy Advice

Katherine Coltrona, Senior Policy Officer

Research Development Unit, Office of the Chief Medical Officer, Clinical Services and Research

Department of Health

Level 2, C Block, 189 Royal Street, EAST PERTH WA 6004

P: 9222 4332

E: katherine.coltrona@health.wa.gov.au